Originally published by sister publication Infectious Disease Special Edition.
Fecal microbiota transplantation (FMT) has unarguably changed the landscape of Clostridioides difficile infection (CDI) management. Now, in its wake is a drug pipeline replete with promising microbiome-based treatments aimed at overcoming some of the safety and logistical challenges of FMT, according to experts.
“Based on the initial success of FMT, the therapeutic world of the microbiome is exploding,”